Electronic data collection of QoL PROMS in Prostate cancer

Not Applicable

Completed

• Conditions: Prostate Cancer; Specialty: Cancer, Primary sub-specialty: Prostate Cancer; UKCRC code/ Disease: Cancer/ Malignant neoplasms of urinary tract; Cancer

• Registration Number: ISRCTN67560441
• Lead Sponsor: Brighton and Sussex University Hospitals NHS Trust

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-12-05
• Study Completion: 2017-07-31
• Last Update Posted: 15 July 2019

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 40

Inclusion Criteria

1. Adult patients > 18 years
2. Diagnosis of prostate cancer not suitable for radical (curative) treatment
3. Commencing palliative systemic therapy (first or subsequent lines) – cytotoxic chemotherapy, modern hormonal agents (including enzalutamide and abiraterone) and radium 223.

Exclusion Criteria

1. Already commenced treatment
2. Treated with androgen deprivation therapy, stilboestrol or dexamethasone only.
3. Treated with trial treatments that are not NICE or Cancer Drug Fund approved

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Feasibility will be assessed by measuring the time taken to complete the questionnaire (collected by electronic data collection system), patient reported feasibility (via feasibility questionnaire) and support needed from the researcher (via feasibility questionnaire) at baseline and 3 months, and measuring the rate of questionnaire completion at 3 months.

Secondary Outcome Measures

Name	Time	Method
<br> 1. Health care professional reported feasibility (all clinic staff including recruiting oncologists) is measured via a HCP feasibility questionnaire at the end of the study<br> 2. Uptake rate (impressions from recruiting doctors( is obtained from HCP feasibility questionnaire at the end of the study<br> 3. Comparison with clinical decision at 3 months is assessed via comparison with decision whether or not to continue treatment and PSA measurement<br> 4. Suitability of tools (sensitivity of tools to change in QoL) is measured via comparison between tools<br>